Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple MyelomaDavid H. Henry, Howard Yeh, Luís Costa et al.|Journal of Clinical Oncology|2011Cited by 1.3k
Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumorsDavid H. Henry, Howard Yeh, Saroj Vadhan‐Raj et al.|Supportive Care in Cancer|2013Cited by 182
A Phase I/II Study of Arsenic Trioxide/Bortezomib/Ascorbic Acid Combination Therapy for the Treatment of Relapsed or Refractory Multiple MyelomaJames R. Berenson, Howard Yeh, Jeffrey Matous et al.|Clinical Cancer Research|2007Cited by 123
Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposureJean‐Jacques Body, Karim Fizazi, Allan Lipton et al.|Journal of Bone and Mineral Research|2009Cited by 120
Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myelomaTorben Plesner, Paul G. Richardson, Carla de Boer et al.|Blood|2016Cited by 110